Sorry I got curious before you could answer the question and did a search.  I see you Doctor dosed you as post menopausal woman and not daily as a  glucocorticoid induced.  Good to see that it actually worked for you on the once weekly dose though.

Cheers

Anne-Marie

Prescription Details:

No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 mL/min). FOSAMAX is not recommended for patients with more severe renal insufficiency (creatinine clearance <35 mL/min) due to lack of experience.

Treatment of osteoporosis in postmenopausal women (see INDICATIONS AND USAGE)

The recommended dosage is:

•	one 70 mg tablet once weekly
or
•	one 10 mg tablet once daily

Treatment to increase bone mass in men with osteoporosis

The recommended dosage is one 10 mg tablet once daily.

Alternatively, one 70 mg tablet once weekly may be considered.

Prevention of osteoporosis in postmenopausal women (see INDICATIONS AND USAGE)

The recommended dosage is:

•	one 35 mg tablet once weekly
or
•	one 5 mg tablet once daily

The safety of treatment and prevention of osteoporosis with FOSAMAX has been studied for up to 7 years.

Treatment of glucocorticoid-induced osteoporosis in men and women

The recommended dosage is one 5 mg tablet once daily, except for postmenopausal women not receiving estrogen, for whom the recommended dosage is one 10 mg tablet once daily.

Paget’s disease of bone in men and women

The recommended treatment regimen is 40 mg once a day for six months.

Retreatment of Paget’s disease

In clinical studies in which patients were followed every six months, relapses during the 12 months following therapy occurred in 9% (3 out of 32) of patients who responded to treatment with FOSAMAX. Specific retreatment data are not available, although responses to FOSAMAX were similar in patients who had received prior bisphosphonate therapy and those who had not. Retreatment with FOSAMAX may be considered, following a six-month post-treatment evaluation period in patients who have relapsed, based on increases in serum alkaline phosphatase, which should be measured periodically. Retreatment may also be considered in those who failed to normalize their serum alkaline phosphatase.